Additionally, thrombophilia screening (including Factor V Leiden, prothrombin gene mutation, protein C/S, and antithrombin III levels) was not completed during the acute phase but remains an important consideration in evaluating stroke in the young. The gene discussed is F2; the disease is Rare hereditary thrombophilia.